CL2013000098A1 - Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. - Google Patents

Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.

Info

Publication number
CL2013000098A1
CL2013000098A1 CL2013000098A CL2013000098A CL2013000098A1 CL 2013000098 A1 CL2013000098 A1 CL 2013000098A1 CL 2013000098 A CL2013000098 A CL 2013000098A CL 2013000098 A CL2013000098 A CL 2013000098A CL 2013000098 A1 CL2013000098 A1 CL 2013000098A1
Authority
CL
Chile
Prior art keywords
potentiated
antibody
formulation
activated
methods
Prior art date
Application number
CL2013000098A
Other languages
English (en)
Spanish (es)
Inventor
Oleg Lliich Epsthein
Alexandrovna Sergeeva Svetlana
Fyodorovna Dologovyh Liudmila
Anatolievna Kheyefets Irina
Leonidovna Dugina Julia
Alexandrovna Zabolotneva Julia
Alexandrovich Tarasov Sergey
Original Assignee
Epsthein Oleg Iliich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000098(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Epsthein Oleg Iliich filed Critical Epsthein Oleg Iliich
Publication of CL2013000098A1 publication Critical patent/CL2013000098A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013000098A 2010-07-15 2013-01-10 Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso. CL2013000098A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома

Publications (1)

Publication Number Publication Date
CL2013000098A1 true CL2013000098A1 (es) 2015-01-16

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000098A CL2013000098A1 (es) 2010-07-15 2013-01-10 Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.

Country Status (30)

Country Link
US (1) US8865163B2 (enExample)
EP (1) EP2593477A2 (enExample)
JP (1) JP2013535436A (enExample)
KR (1) KR20140012009A (enExample)
CN (1) CN103124742A (enExample)
AR (1) AR082246A1 (enExample)
AU (1) AU2011278040B2 (enExample)
BR (1) BR112013000841A2 (enExample)
CA (1) CA2805091A1 (enExample)
CL (1) CL2013000098A1 (enExample)
CZ (1) CZ2013104A3 (enExample)
DE (1) DE112011102349T5 (enExample)
DK (1) DK201370078A (enExample)
EA (1) EA029400B1 (enExample)
EE (1) EE05760B1 (enExample)
ES (1) ES2542042R1 (enExample)
FI (1) FI20135146L (enExample)
FR (1) FR2962653A1 (enExample)
GB (1) GB2496076B (enExample)
IT (1) ITTO20110641A1 (enExample)
LT (1) LT5987B (enExample)
MX (1) MX361778B (enExample)
MY (1) MY158183A (enExample)
NO (1) NO20130219A1 (enExample)
NZ (1) NZ606768A (enExample)
PE (1) PE20131338A1 (enExample)
PH (1) PH12013500109A1 (enExample)
SE (1) SE1350179A1 (enExample)
SG (1) SG187037A1 (enExample)
WO (1) WO2012007847A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
MX2013000543A (es) 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962655A1 (fr) * 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et ses utilisations dans les procedes de traitement des troubles du systeme genito-urinaire
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
CN103118707A (zh) * 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法
FR2962909A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees avec une maladie ou affection respiratoire
US20130058981A1 (en) * 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
CZ2013159A3 (cs) * 2010-08-06 2013-06-12 Iliich Epshtein@Oleg Kombinovaná farmaceutická kompozice a zpusoby lécby a prevence infekcních chorob
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
JP6598844B2 (ja) * 2014-03-27 2019-10-30 バード・ロック・バイオ・インコーポレイテッド ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
JP2019502651A (ja) * 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
CN114375200A (zh) * 2019-08-29 2022-04-19 奥列格·伊利奇·爱泼斯坦 治疗传染病的药物和方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
AU723812B2 (en) 1996-02-12 2000-09-07 Oleg Iliich Epshtein Medicinal preparation and a method of medicinal action on human organism
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
CA2654408C (en) * 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
AR063497A1 (es) * 2006-10-23 2009-01-28 Lilly Co Eli Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
MY157564A (en) 2010-07-15 2016-06-30 Epshtein Oleg Lliich Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
US20130058981A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
WO2012010978A2 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating alzheimer's disease
WO2012014078A2 (en) 2010-07-21 2012-02-02 Olge Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
CN103118707A (zh) 2010-07-21 2013-05-22 奥列格·伊里奇·爱泼斯坦 复合药物组合物及对糖尿病和代谢紊乱进行治疗的方法

Also Published As

Publication number Publication date
FI20135146A7 (fi) 2013-02-15
AU2011278040A1 (en) 2013-03-07
DE112011102349T5 (de) 2013-04-18
EE05760B1 (et) 2016-03-15
NZ606768A (en) 2015-08-28
AR082246A1 (es) 2012-11-21
FI20135146L (fi) 2013-02-15
ES2542042A2 (es) 2015-07-29
CZ2013104A3 (cs) 2013-05-29
CA2805091A1 (en) 2012-01-19
GB2496076B (en) 2018-05-09
AU2011278040B2 (en) 2016-06-02
JP2013535436A (ja) 2013-09-12
GB201302653D0 (en) 2013-04-03
ITTO20110641A1 (it) 2012-01-16
GB2496076A (en) 2013-05-01
SE1350179A1 (sv) 2013-04-12
SG187037A1 (en) 2013-02-28
NO20130219A1 (no) 2013-03-22
ES2542042R1 (es) 2015-10-06
CN103124742A (zh) 2013-05-29
LT5987B (lt) 2014-01-27
BR112013000841A2 (pt) 2016-06-07
PE20131338A1 (es) 2013-11-18
EA029400B1 (ru) 2018-03-30
MY158183A (en) 2016-09-15
PH12013500109A1 (en) 2015-07-03
WO2012007847A2 (en) 2012-01-19
MX2013000545A (es) 2013-10-28
US8865163B2 (en) 2014-10-21
EP2593477A2 (en) 2013-05-22
US20130017202A1 (en) 2013-01-17
KR20140012009A (ko) 2014-01-29
EE201300005A (et) 2013-08-15
MX361778B (es) 2018-12-17
DK201370078A (en) 2013-02-14
EA201300133A1 (ru) 2014-03-31
LT2013015A (lt) 2013-11-25
FR2962653A1 (fr) 2012-01-20
WO2012007847A3 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112013003238A2 (pt) “sistema para preparar uma bebida, dispositivo de preparação de bebida, cápsula, kit, e, uso de uma cápsula”
BR112013018877A2 (pt) composições farmacêuticas que compreendem anticorpos humanos para pcsk9
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
CL2012002737A1 (es) Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
CL2013003329A1 (es) Molécula de union a cd3 que comprende un dominio variable de cadena ligera (vl) y un dominio variable de cadena pesada (vh) capaz de unir un epitope de cd3 humano y de mamiferos no humanos; composición farmacéutica que comprende dicha molécula; y uso para preparar un medicamento.
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BRPI0917661A2 (pt) produto que contém macitentan, composição farmacêutica que o contém e uso de macitentan
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
BR112012012969A2 (pt) '' formulação farmacêutica líquida e uso de um antioxidante''
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
CL2014002019A1 (es) Anticuerpos anti - asic1; composicion farmaceutica que lo comprende y usos de los mismos.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
BR112013014189A8 (pt) composição farmacêutica, uso de um agente de potencialização e uso de uma composição
BRPI1009781A2 (pt) compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2013001564A1 (es) Metodo para tratar sobrepeso u obesidad que comprende administrar naltrexona y bupropion; metodo para incrementar la biodisponibilidad de naltrexona y bupropion en una terapia combinada; uso de naltrexona y bupropion para tratar sobrepeso u obesisdad e incrementar la biodisponibilidad de estos farmacos; composicion farmaceutica.
BR112014021068A8 (pt) inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor